Population Genetics Technologies Receives $3.2M in Series A Funding | GenomeWeb

NEW YORK (GenomeWeb News) – Population Genetics Technologies said today that it has secured a £2,000,000 ($3.2 million) investment from previous investors in the privately held genomics analysis technologies firm.

The company said it earned this second tranche of the Series A funding by meeting certain commercial and developmental milestones set by its principal investors.

The Cambridge, UK-based firm's initial seed funding came from the Wellcome Trust, and its Series A investors include Auriga Partners, Beringea, and Compass Genetics Investors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.